Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Phase 1 N=23 A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults
Healthy Participants
Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants
Phase 1 N=23 A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
N/A N=37 Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
Skin Diseases
Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids
Phase 1 N=12 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
Pharmacokinetics · Healthy Volunteers
Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter
Phase 1 N=18 A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers
Malaria
Primary: Cmax: Peak Plasma Concentration — 277; 373.4444 ng/mL
Phase 1 N=48 Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers
Malaria
Primary: Number of Participants With Adverse Events — 4; 5; 5; 6 Participants
Phase 1 N=56 Dose-finding Pharmacokinetic Study in Healthy Males
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Phase 1 N=12 A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
Phase 1 N=60 Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers
Healthy
Primary: Number of Subjects With Drug Related Adverse Events — 5; 1; 0; 0 Participants
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=18 A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers
Epilepsy
Primary: Number of Adverse Events Reported — 10; 7; 7 Number of adverse events reported
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
Phase 1 N=18 A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06821497 — 3302; 3375; 3479; 11220 ng*hr/mL
Phase 1 N=8 First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events
Phase 1 N=97 Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers
Healthy
Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants
Phase 1 N=9 A GBT021601 ADME Microtracer Study in Healthy Volunteers
Sickle Cell Disease
Primary: GBT021601 Concentration in Whole Blood and Plasma at Predose — NA; NA Microgram/ milliliter (mcg/mL)
Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
Phase 1 N=5 Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
Healthy
Primary: The Mean (SD) Amount of [14C] Recovered in Urine, as a Percent of the Total [14C] Dose Administered — 25.2 percentage of dose
Phase 2 N=25 Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects
Healthy
Primary: Age-Dependent Change in Striatal 18F-DTBZ Uptake of Healthy Subjects. — 0.05 SUVR
Phase 1 N=11 Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 Days
Healthy
Primary: AUCτ Over a Dosing Interval (τ = 12 Hours) on Day 14 — 12090.998; 23472.1329; 30005.781; 50354.938 ng*h/mL
Phase 1 N=65 Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers
Healthy
Primary: Percentage (%) of Subjects With Drug-related Adverse Events (AEs) — 13.3; 9.1; 36.4; 57.9 Percentage of Participants
Phase 1 N=70 A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 40.0; 75.0; 50.0; 75.0 Percentage of participants
Phase 1 N=82 A Study of LY3484356 in Healthy Female Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1) — 1810; 4350 nanogram*hour per milliliter…
Phase 1 N=25 Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Healthy
Primary: Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 6147; 6141 nanomol…
Phase 1 N=12 A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
Healthy Volunteers · Adult · Pharmacokinetics
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…
Phase 1 N=52 A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
Biological Availability
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant — 83.65; 102.5; 184.4; 47.29 Hours*nanograms per milliliter (h*ng/mL)
Phase 1 N=8 A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers
Smoking Cessation
Primary: Number of Adverse Events — 5; 0; 1; 1 Participants